Scientists have spotted a new variety of riled-up microglia that drives swelling in the human brain. In the November 18 Neuron, researchers from China led by Haixiao Liu, Shunnan Ge, and Yan Qu at ...

As lecanemab gains regulatory approval in more countries (see previous story), clinicians are eager to learn from the first centers to have incorporated this therapeutic antibody into their clinical ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating ...

As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

Now that lecanemab has been in clinical use in the U.S. for a little over a year, doctors are asking how long they should treat. This remains an open question. Drug maker Eisai has proposed to the FDA ...

A new multiplex diagnostic method appears poised to resculpt the biomarker landscape. NULISA, aka NUcleic acid Linked Immunosorbent Assay, can detect Aβ peptides, p-tau isoforms, and other potential ...

The revelation that tau aggregates can pass between cells, corrupting their intracellular counterparts, changed how the Alzheimer’s field studies tau pathology. At this year’s AD/PD meeting, held in ...

In Phase 3, HMTM failed to meet co-primary endpoints. Subgroup analysis of an open-label extension suggests benefit in people with MCI. In that subgroup, half as many people transitioned to AD. HMTM ...